Expression and signification of transferrin receptor 1 in head-neck carcinoma_West China Medical Journal

Authors：

NI Xiaowei , JIANG Ying ,  TANG Yuedi

Department of Otolaryngology-Head and Neck Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P. R. China;

Corresponding?author：

TANG Yuedi, Email: tangyd@hotmail.com

Keywords：

Transferrin receptor 1; Carcinoma; Western blot

DOI：

10.7507/1002-0179.201703181

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To detect the expression of transferrin receptor 1 (TfR1) in laryngeal carcinoma, thyroid carcinoma, maxillary sinus carcinoma, and parotid carcinoma, exploring the relationship between the expression of the four cancers and their occurrence and progression. Methods A total of 24 specimens of head-neck carcinoma were collected in surgery from April 2015 to March 2017, including 8 cases of laryngeal carcinoma, 8 cases of thyroid carcinoma, 4 cases of maxillary sinus carcinoma, and 4 cases of parotid carcinoma. Fluorescence quantitative polymerase chain reaction technique for TfR1 mRNA and western blot for TfR1 protein was performed in those tumor tissues and their adjacent normal tissues. Results The relative expression level of TfR1 mRNA in the tumor tissues of laryngeal carcinoma, thyroid carcinoma, maxillary sinus carcinoma, and parotid carcinoma was 0.078±0.002, 0.065±0.044, 0.076±0.014, 0.067±0.004, respectively; while the relative expression level of TfR1 mRNA in the adjacent normal tissues of the four cancers was 0.021±0.012, 0.011±0.007, 0.017±0.013, 0.028±0.007, respectively. The relative expression level of TfR1 protein in the tumor tissues of laryngeal carcinoma, thyroid carcinoma, maxillary sinus carcinoma, and parotid carcinoma was 0.668±0.206, 0.640±0.066, 0.452±0.095, 0.925±0.221, respectively; while the relative expression level of TfR1 protein in the adjacent normal tissues of the four cancers was 0.359±0.113, 0.424±0.096, 0.280±0.093, 0.519±0.037, respectively. The expression levels of TfR1 mRNA and TfR1 protein in the tumor tissues of the four cancers were all higher than those in their adjacent normal tissues (P<0.05). Conclusions The expression levels of TfR1 mRNA and TfR1 protein in the tumor tissues of laryngeal carcinoma, thyroid carcinoma, maxillary sinus carcinoma and parotid carcinoma are up-regulated. TfR1 may be involved in the occurrence and progression of the four cancers, and it may be responsible for tumor proliferation by providing necessary raw materials for the proliferation of tumor cells.

Citation： NI Xiaowei, JIANG Ying, TANG Yuedi. Expression and signification of transferrin receptor 1 in head-neck carcinoma. West China Medical Journal, 2017, 32(11): 1726-1729. doi: 10.7507/1002-0179.201703181 Copy

1.	Siegel R, Jemal A, Ma Jiemin, et al. Cancer statistics, 2014. CA Cancer J Clin, 2014, 64(1): 9-29.
2.	鄧太海, 陳舒華. 轉鐵蛋白受體與腫瘤疾病的關系. 海南醫學, 2011, 22(5): 137-140.
3.	陳玥琦. 轉鐵蛋白受體與腫瘤疾病的關系. 實用腫瘤學雜志, 2015, 29(1): 65-68.
4.	張洪明. 轉鐵蛋白受體的結構、表達及功能. 實用臨床醫藥雜志, 2008, 12(5): 114-117.
5.	Leplletier Y, Camara-Clayette V, Jin H, et al. Prevemion of mantle lymphoma tumor establishment by routing transferrin receptor toward lysosomal compartments. Cancer Res, 2007, 67(3): 1145-1154.
6.	Daniels TR, Delgado T, Rodriguez JA, et al. The transferrin receptor part I: biology and targeting with cytotoxic antibodies for the treatment of cancer. Clin Immunol, 2006, 121(2): 144-158.
7.	Giannetti AM, Snow PM, Zak O, et al. Mechanism for multiple ligand recognition by the human transferring receptor. PLoS Biol, 2003, 1(3): E51.
8.	陳舒華, 周少雄, 張繼平, 等. 鼻咽癌高癌家系癌患者不同體質證型的蛋白質組學研究. 中國中西醫結合耳鼻咽喉科雜志, 2013, 21(1): 5-9.
9.	Panieri E. Breast cancer screening in developing countries. Best Pract Res Clin Obstet Gynaecol, 2012, 26(2): 283-290.
10.	原永明, 周雪穎, 韓倩, 等. 肝癌患者血清鐵含量檢測的臨床意義. 檢驗醫學, 2013, 28(6): 534-535.
11.	Theler JM. Bone tissue substitutes and replacements. Curr Opin Otolaryngol Head Neck Surg, 2011, 19(4): 317-321.
12.	劉雙林, 王志華, 胡志全, 等. 抗人轉鐵蛋白受體單克隆抗體增強姜黃素對雄激素非依賴性前列腺癌的抑制效應. 華中科技大學學報: 醫學版, 2012, 41(3): 284-287, 295.
13.	張莉, 徐維平, 陸楊, 等. 轉鐵蛋白-轉鐵蛋白受體在腫瘤主動靶向治療中的應用. 中國藥業, 2012, 5(21): 1-3.
14.	Zhang MX, Gurnerov DR, Kaltashov IA. Indirect detection of protein-metal binding: interaction of serum transferrin with In³⁺ and Bi³⁺. J Am Soc Mass Spectrom, 2004, 15(11): 1658-1664.
15.	王叢珠, 王登平, 鄭佐婭. 轉鐵蛋白介導作用的應用進展. 放射免疫學雜志, 2003, 16(5): 304-306.
16.	汪溪, 李建業, 夏春咸. 雙氫青蒿素抗腫瘤作用研究進展. 海南醫學, 2010, 21(13): 119-121.
17.	Efferth T, Benakis A, Romero MR, et al. Enhancement of cytotoxicity of artemisinins toward cancer cells by ferrous iron. Free Radic Biol Med, 2004, 37(7): 998-1009.
18.	Sadava D, Phillips T, Lin C, et al. Transferrin overcomes drug resistance to artemisinin in human small-cell lung carcinoma cells. Cancer Lett, 2002, 179(2): 151-156.

1. Siegel R, Jemal A, Ma Jiemin, et al. Cancer statistics, 2014. CA Cancer J Clin, 2014, 64(1): 9-29.
2. 鄧太海, 陳舒華. 轉鐵蛋白受體與腫瘤疾病的關系. 海南醫學, 2011, 22(5): 137-140.
3. 陳玥琦. 轉鐵蛋白受體與腫瘤疾病的關系. 實用腫瘤學雜志, 2015, 29(1): 65-68.
4. 張洪明. 轉鐵蛋白受體的結構、表達及功能. 實用臨床醫藥雜志, 2008, 12(5): 114-117.
5. Leplletier Y, Camara-Clayette V, Jin H, et al. Prevemion of mantle lymphoma tumor establishment by routing transferrin receptor toward lysosomal compartments. Cancer Res, 2007, 67(3): 1145-1154.
6. Daniels TR, Delgado T, Rodriguez JA, et al. The transferrin receptor part I: biology and targeting with cytotoxic antibodies for the treatment of cancer. Clin Immunol, 2006, 121(2): 144-158.
7. Giannetti AM, Snow PM, Zak O, et al. Mechanism for multiple ligand recognition by the human transferring receptor. PLoS Biol, 2003, 1(3): E51.
8. 陳舒華, 周少雄, 張繼平, 等. 鼻咽癌高癌家系癌患者不同體質證型的蛋白質組學研究. 中國中西醫結合耳鼻咽喉科雜志, 2013, 21(1): 5-9.
9. Panieri E. Breast cancer screening in developing countries. Best Pract Res Clin Obstet Gynaecol, 2012, 26(2): 283-290.
10. 原永明, 周雪穎, 韓倩, 等. 肝癌患者血清鐵含量檢測的臨床意義. 檢驗醫學, 2013, 28(6): 534-535.
11. Theler JM. Bone tissue substitutes and replacements. Curr Opin Otolaryngol Head Neck Surg, 2011, 19(4): 317-321.
12. 劉雙林, 王志華, 胡志全, 等. 抗人轉鐵蛋白受體單克隆抗體增強姜黃素對雄激素非依賴性前列腺癌的抑制效應. 華中科技大學學報: 醫學版, 2012, 41(3): 284-287, 295.
13. 張莉, 徐維平, 陸楊, 等. 轉鐵蛋白-轉鐵蛋白受體在腫瘤主動靶向治療中的應用. 中國藥業, 2012, 5(21): 1-3.
14. Zhang MX, Gurnerov DR, Kaltashov IA. Indirect detection of protein-metal binding: interaction of serum transferrin with In³⁺ and Bi³⁺. J Am Soc Mass Spectrom, 2004, 15(11): 1658-1664.
15. 王叢珠, 王登平, 鄭佐婭. 轉鐵蛋白介導作用的應用進展. 放射免疫學雜志, 2003, 16(5): 304-306.
16. 汪溪, 李建業, 夏春咸. 雙氫青蒿素抗腫瘤作用研究進展. 海南醫學, 2010, 21(13): 119-121.
17. Efferth T, Benakis A, Romero MR, et al. Enhancement of cytotoxicity of artemisinins toward cancer cells by ferrous iron. Free Radic Biol Med, 2004, 37(7): 998-1009.
18. Sadava D, Phillips T, Lin C, et al. Transferrin overcomes drug resistance to artemisinin in human small-cell lung carcinoma cells. Cancer Lett, 2002, 179(2): 151-156.

West China Medical Journal

Expression and signification of transferrin receptor 1 in head-neck carcinoma

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content